58046-54-1

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-1-PHENYL-1H-PYRAZOLE-4-CARBOHYDRAZIDE is used as a drug candidate for the development of central nervous system medications due to its potent monoamine oxidase inhibitory activity.
Used in Treatment of Neurological Disorders:
5-AMINO-1-PHENYL-1H-PYRAZOLE-4-CARBOHYDRAZIDE is used as a potential therapeutic agent for conditions such as depression, anxiety, and Parkinson's disease, leveraging its ability to inhibit the breakdown of key neurotransmitters.
Used in Cancer Therapy Research:
5-AMINO-1-PHENYL-1H-PYRAZOLE-4-CARBOHYDRAZIDE is used as a subject of investigation in cancer research for its potential to inhibit tumor growth and proliferation, although further studies are required to confirm its efficacy and safety in this context.

InChI:InChI=1/C10H11N5O/c11-9-8(10(16)14-12)6-13-15(9)7-4-2-1-3-5-7/h1-6H,11-12H2,(H,14,16)

Upstream product

• 16078-71-0 ethyl 5-amino-1-phenyl-1H-pyrazole-4-carboxylate 
• 59-88-1 phenylhydrazine hydrochloride 
• 100-63-0 phenylhydrazine 
• 99347-02-1 Ethyl 5-(dibenzoylamino)-1-phenyl-1H-pyrazole-4-carboxylate 

Downstream Products

• 99347-11-2 5-Formylamino-1,5-dihydro-1-phenyl-4H-pyrazolo<3,4-d>pyrimidin-4-one 
• 110810-02-1 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid cyclohexylidene-hydrazide 
• 110810-11-2 C₁₇H₂₁N₅O 
• 110810-00-9 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid [1-phenyl-meth-(E)-ylidene]-hydrazide 
• 110809-97-7 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid eth-(E)-ylidene-hydrazide 
• 64257-07-4 5-amino-1,5-dihydro-6-methyl-1-phenyl-4H-pyrazolo<3,4-d>pyrimidin-4-one 
• 99347-10-1 Ethyl N'-(5-amino-1-phenyl-1H-pyrazol-4-yl)acetohydrazonate 
• 99347-09-8 5-(Ethoxymethylenamino)-1,5-dihydro-1-phenyl-4H-pyrazolo<3,4-d>pyrimidin-4-one 
• 110810-05-4 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid [1-phenyl-eth-(E)-ylidene]-hydrazide 
• 110810-01-0 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid isopropylidene-hydrazide 
• 99378-02-6 5-Amino-1-phenyl-1H-pyrazolo<3,4-d>pyrimidine-4,6(5H,7H)-dione 
• 198716-12-0 5-(5-amino-1-phenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole-2-thiol 
• 198715-89-8 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-chloro-phenyl)-meth-(Z)-ylidene]-hydrazide 
• 198715-90-1 5-Amino-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-nitro-phenyl)-meth-(Z)-ylidene]-hydrazide 

Relevant academic research and scientific papers

New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies

Two new series of hybrid structures 16a-f and 19a-f containing 1,2,4-triazole moiety, pyrazole core with COX-2 pharmacophore and oxime as NO donor moiety were designed, synthesized and evaluated for anti-inflammatory, cytotoxic activities and NO release. All compounds were more selective for COX-2 isozyme especially the sulphamoyl derivatives (16b, 16e, 19b and 19e) had COX-2 selectivity indexes (S.I. = 9.78, 8.57, 10.78 and 10.47 respectively) in comparison to celecoxib (S.I. = 8.68). Similarly, 16b, 16e, 19b and 19e were the most potent anti-inflammatory derivatives with ED50 = 46.98–54.45 μmol/kg better than celecoxib (ED50 = 76.09 μmol/kg). Also, 16b, 16e, 19b and 19e were significantly less ulcerogenic (ulcer indexes = 2.79–3.95) upon comparison with ibuprofen (ulcer index = 20.25) and comparable with celecoxib (ulcer index = 2.93). Regarding anti-cancer activity, most of the target derivatives 16a-f and 19a-f showed good activities against A-549, MCF-7, HCT-116 and PC-3 cancer cell lines. Additionally, these derivatives examined against F180 fibroblasts to investigate their selectivity indexes. The sulphamoyl derivatives with internal oxime 19b and 19e were the most potent derivatives against all used cell lines especially PC-3 (IC50 = 1.48 and 0.33 μM respectively) with 11.75 and 39.4-fold respectively selectivity towards PC-3 than F180 fibroblasts. The mechanistic investigation of 19b and 19e revealed that both compounds arrested cell cycle at G2/M phase by 32.16 and 39.95 folds, up-regulated Bax expression by 6.83 and 14.52 folds and down-regulated the expression of the gene Bcl-2 by 0.57 and 0.36fold respectively. Also, 19b and 19e were good inhibitor for p38MAPK (0.65 for 19b and 0.58 for 19e) and VEGFR-2 (0.39 for 19b and 0.54 for 19e) in comparison with PC-3 control cell. All compounds 16a-f and 19a-f released NO in a slow rate (0.15–3.17%) and the four sulphamoyl derivatives 16b, 16e, 19b and 19e were the most NO releasers (3.06, 2.15, 3.17 and 2.54% respectively). Docking studies were carried out to explain the interaction of 16a-f and 19a-f with the target enzymes. Docking mode of final designed compounds with celecoxib (ID: 3LN1) represented that their triazole ring adopted as the core aryl in Y shaped structure. Regarding EGFR inhibition, docking was carried out with ID: 1M17. The internal oxime serious was more active as anticancer because of their ability to form extra HBs with receptor cleft.

1-phenyl-5-amino-4-pyrazole bi-oxadiazole thioether compounds and application thereof

The invention discloses a preparation method for 1-phenyl-5-amino-4-pyrazole bi-oxadiazole thioether compounds and an application in tobacco mosaic virus resistant activity. The compounds have structures represented by a general formula (I) in the description. The method provided by the invention is based on a 5-amino-1-(3-chloro-2-pyridyl)-4-(5-methylthio-1,3,4-oxadiazole-2-yl)-pyrazole structureand uses ''phenyl'' to replace ''3-chloro-2-pyridyl'' on the 1-position of a pyrazole ring to synthesize a series of the 1-phenyl-5-amino-4-pyrazole bi-oxadiazole thioether compounds, and experimentsof the compounds in vivo show that the compounds have good curative protective and inactivating activity on virus diseases caused by the tobacco mosaic virus (TMV), and the compounds show significanteffects on passivation effects compared with compounds reported in the earlier work of a research group; and the compounds provide an important scientific basis for the research, development, creation of novel pesticides.

NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME

Organic electroluminescent compounds of Chemical Formula 1 : wherein the variables A1, A2, A3, A4, R1 and R2 are as defined therein in the specification. These compounds exhibit high luminous efficiency and excellent life property of material and are used in organic electroluminescent devices. An OLED having a very good operation life and improved consumption power is manufactured using these compounds.

Synthesis and herbicidal activities of a series of di(aminopyrazoly) ketone derivatives

(Chemical Equation Presented) In order to obtain new lead compounds with high herbicidal activity, a series of 5-amino pyrazole derivatives were designed and synthesized using a series of relational synthons. Their structures were determined by IR, 1H NMR, and elemental analyses. These compounds were screened for herbicidal activities against rape and barnyard grass. Their structure-activity relationships are discussed.

Facile synthesis of 1-substituted 4,5-diaminopyrazoles and its application toward the synthesis of pyrazolo[3,4-b]pyrazines

1-Substituted 5-aminopyrazole-4-carbonylazides were prepared from the appropriate 5-aminopyrazole-4-carboxylates. The acyl azides undergo a Curtius rearrangement followed by quenching with alcohols to form the corresponding carbamates. The 1-substituted 5

Heterocyclic β-Enamino Esters, 39. - Synthesis of 1H-Pyrazolopyrimidines

Die Pyrazol-Enaminoester 1a, b und 4-Pyrazolcarbohydrazide 4a, b sind nuetzliche Ausgangsverbindungen fuer die Darstellung von 1H-Pyrazolopyrimidinen.So ergeben Orthoameisensaeure- und Orthoessigsaeure-triethylester mit 4a, b die 5-(Ethoxymethylena